NCT00788125: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy, Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 25 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients must have brain metastases that have been completely resected just prior to study; Breast cancer patients are only eligible for phase 1
Exclusions: Patients with prior cranial-spinal irradiation at doses at greater than 2,400 cGy

Comments are closed.

Up ↑